Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bexsero

- PMLiVE

GSK set for 2017 European rollout of med device asthma app

Updated version of the MyAsthma iPhone app is firm's first Class 1 med device

- PMLiVE

GSK starts late-stage trials of daprodustat

Drug hopes to treat anaemia caused by chronic kidney disease

- PMLiVE

GSK’s Bexsero vaccine growing fast, despite “tight” supply

Meningitis drug’s sales double as third quarter results exceed expectations

- PMLiVE

Pharma ramps up its use of Instagram

GSK became the latest firm to join the social network, signing up last month

- PMLiVE

GSK and J&J file sirukumab for rheumatoid arthritis in EU

If approved it will compete with Roche blockbuster Actemra

- PMLiVE

Bexsero halved UK meningitis B cases in first year, says study

GSK hopes success of its UK vaccination campaign will encourage replication worldwide

- PMLiVE

GSK launches first pharma trial powered by Apple’s ResearchKit

Will use an iPhone app built using the software for a real-world study

- PMLiVE

GSK signs up for the ‘dawn of cognitive advertising’

Its consumer health arm is among the first to use new IBM offering Watson Ads

- PMLiVE

GSK’s chief executive Sir Andrew Witty to retire next year

The announcement follows months of speculation about his position

- PMLiVE

GSK appoints rare diseases research head

Birgitte Volck moves to the company from Swedish Ophan Biovitrum

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

- PMLiVE

GSK’s severe asthma therapy Nucala gets EU nod

Becomes the first IL-5 inhibitor to be approved in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links